Clinical trial
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2…
NCT00471081 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00471081 |
|---|---|
| Title | Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers. |
| Official title | Study to Assess Immunogenicity, Reactogenicity and Safety of Primary Vaccination With GSK Biologicals' MenACWY Vaccine (GSK134612) Given as 1 or 2 Doses to Healthy Toddlers 9-12 Months of Age |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Infections, Meningococcal |
| Intervention type | Biological |
| Interventions | Meningococcal vaccine GSK134612 |
| Enrollment | 385 |
| Start date | Jul 5, 2007 |
| Primary completion | Oct 23, 2008 |
| Completion | Nov 26, 2008 |
| First posted | May 9, 2007 |
| Last update posted | Jun 25, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: